However, the identification of a new allosteric target in the switch pocket II region of the KRAS G12C mutation that can covalently bind with specific inhibitors and subsequently induce apoptosis paves the way for therapeutic developments of the first KRAS inhibitors.8,9 The FDA has since approved AMG510 (sotorasib) and MTRX849 (adagrasib) for the treatment of lung adenocarcinoma.10 These developments have led to increased vigor in the development of inhibitors specifically targeting KRAS. This evidence concerns the gene KRAS and lung adenocarcinoma.